Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.
From the official U.S. FDA label for sildenafil (sildenafil citrate), the active ingredient registered with NAFDAC.
Sildenafil citrate is indicated for the treatment of erectile dysfunction. Sildenafil citrate is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) ( 1 )
The following are discussed in more detail in other sections of the labeling: Cardiovascular [ see Warnings and Precautions ( 5.1 ) ] Prolonged Erection and Priapism [ see Warnings and Precautions ( 5.2 ) ] Effects on the Eye [ see Warnings and Precautions ( 5.3 ) ] Hearing Loss [ see Warnings and Precautions ( 5.4 ) ] Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives [ see Warnings and Precautions ( 5.5 ) ] Adverse Reactions with the Concomitant Use of Ritonavir [ see Warnings and Precautions ( 5.6 ) ] Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [ see Warnings and Precautions ( 5.7 ) ] Effects on Bleeding [ see Warnings and Precaut …
Administration of sildenafil tablets to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. Sildenafil citrate was shown to potentiate the hypotensive effect of nitrates ( 4.1 , 7.1 , 12.2 ) Known hypersensitivity to sildenafil or any component of tablet ( 4.2 ) Administration with guanylate cyclase (GC) stimulators, such as riociguat ( 4.3 ) 4.1 Nitrates Consistent with its known effects on the nitric oxide/cGMP pathway [ see Clinical Pharmacology ( 12. …
Patients should not use sildenafil tablets if sexual activity is inadvisable due to cardiovascular status ( 5.1 ) Patients should seek emergency treatment if an erection lasts >4 hours. Use sildenafil tablets with caution in patients predisposed to priapism ( 5.2 ) Patients should stop sildenafil tablets and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). Sildenafil tablets should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a “crowded” optic disc may also be at an increased risk of NAION. …
8.1 Pregnancy Risk Summary Sildenafil tablets are not indicated for use in females. There are no data with the use of sildenafil citrate in pregnant women to inform any drug-associated risks for adverse developmental outcomes. Animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to 16 and 32 times, respectively, the maximum rec …
Add the expiry date on your pack for a full Trust Score.
Venegray 50 Tablets contains Sildenafil (Sildenafil Citrate) (50 mg), as tablet, according to its NAFDAC registration record.
Yes. Venegray 50 Tablets is listed on the NAFDAC register under registration number B4-7349, and its registration is active as of 27 October 2026.
No WHO falsified or substandard medical product alert currently matches Venegray 50 Tablets in our automatically synced alert list.
Run a free authenticity scan with the NAFDAC number B4-7349, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.
Sildenafil citrate is indicated for the treatment of erectile dysfunction. Sildenafil citrate is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) ( 1 ) (Summarised from the official U.S. FDA label for sildenafil (sildenafil citrate). Always follow your doctor or pharmacist.)
Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.